JP2013503642A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013503642A5 JP2013503642A5 JP2012528058A JP2012528058A JP2013503642A5 JP 2013503642 A5 JP2013503642 A5 JP 2013503642A5 JP 2012528058 A JP2012528058 A JP 2012528058A JP 2012528058 A JP2012528058 A JP 2012528058A JP 2013503642 A5 JP2013503642 A5 JP 2013503642A5
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- antibody
- subject
- cdna
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 5
- 230000001064 anti-interferon Effects 0.000 claims 4
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- 239000002299 complementary DNA Substances 0.000 claims 3
- 108020004999 messenger RNA Proteins 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 101000840275 Homo sapiens Interferon alpha-inducible protein 27, mitochondrial Proteins 0.000 claims 2
- 101001082070 Homo sapiens Interferon alpha-inducible protein 6 Proteins 0.000 claims 2
- 101000840293 Homo sapiens Interferon-induced protein 44 Proteins 0.000 claims 2
- 101000959664 Homo sapiens Interferon-induced protein 44-like Proteins 0.000 claims 2
- 101000657037 Homo sapiens Radical S-adenosyl methionine domain-containing protein 2 Proteins 0.000 claims 2
- 102100029604 Interferon alpha-inducible protein 27, mitochondrial Human genes 0.000 claims 2
- 102100027354 Interferon alpha-inducible protein 6 Human genes 0.000 claims 2
- 102100029607 Interferon-induced protein 44 Human genes 0.000 claims 2
- 102100039953 Interferon-induced protein 44-like Human genes 0.000 claims 2
- 102100033749 Radical S-adenosyl methionine domain-containing protein 2 Human genes 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 102000002227 Interferon Type I Human genes 0.000 claims 1
- 108010014726 Interferon Type I Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23963009P | 2009-09-03 | 2009-09-03 | |
| US61/239,630 | 2009-09-03 | ||
| PCT/US2010/047721 WO2011028933A1 (en) | 2009-09-03 | 2010-09-02 | Type 1 interferon diagnostic |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015075518A Division JP2015147788A (ja) | 2009-09-03 | 2015-04-02 | Ｉ型インターフェロン診断法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013503642A JP2013503642A (ja) | 2013-02-04 |
| JP2013503642A5 true JP2013503642A5 (enExample) | 2013-10-17 |
| JP5727484B2 JP5727484B2 (ja) | 2015-06-03 |
Family
ID=43649646
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012528058A Expired - Fee Related JP5727484B2 (ja) | 2009-09-03 | 2010-09-02 | Ｉ型インターフェロン診断法 |
| JP2015075518A Pending JP2015147788A (ja) | 2009-09-03 | 2015-04-02 | Ｉ型インターフェロン診断法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015075518A Pending JP2015147788A (ja) | 2009-09-03 | 2015-04-02 | Ｉ型インターフェロン診断法 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20120251546A1 (enExample) |
| EP (1) | EP2473636B1 (enExample) |
| JP (2) | JP5727484B2 (enExample) |
| KR (1) | KR20120101340A (enExample) |
| CN (1) | CN102753704A (enExample) |
| AU (1) | AU2010289383B2 (enExample) |
| BR (1) | BR112012004781A2 (enExample) |
| CA (1) | CA2772921A1 (enExample) |
| CY (1) | CY1118566T1 (enExample) |
| DK (1) | DK2473636T3 (enExample) |
| ES (1) | ES2613055T3 (enExample) |
| HR (1) | HRP20170091T1 (enExample) |
| HU (1) | HUE032917T2 (enExample) |
| LT (1) | LT2473636T (enExample) |
| ME (1) | ME02599B (enExample) |
| MX (1) | MX2012002640A (enExample) |
| PL (1) | PL2473636T3 (enExample) |
| PT (1) | PT2473636T (enExample) |
| RS (1) | RS55641B1 (enExample) |
| RU (1) | RU2012112802A (enExample) |
| SI (1) | SI2473636T1 (enExample) |
| SM (2) | SMT201700063T1 (enExample) |
| WO (1) | WO2011028933A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1552021A4 (en) * | 2002-06-11 | 2006-06-14 | Idaho Res Foundation | INTERFERON TYPE I INDUCIBLE PROTEINS FOR THE DETECTION OF VIRUS INFECTION |
| RU2527068C2 (ru) * | 2006-12-06 | 2014-08-27 | Медиммун, Ллк | Фармакодинамические маркеры, индуцированные интерфероном альфа |
| JP2010526107A (ja) * | 2007-05-03 | 2010-07-29 | メディミューン，エルエルシー | 自己免疫疾患の自己抗体マーカー |
| WO2012149228A1 (en) * | 2011-04-26 | 2012-11-01 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| WO2013101771A2 (en) * | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| JP2015526391A (ja) * | 2012-06-13 | 2015-09-10 | メディミューン，エルエルシー | 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン |
| JP6531306B2 (ja) * | 2015-02-20 | 2019-06-19 | 一三 西野 | 炎症性筋疾患鑑別マーカー及びそれを用いた炎症性筋疾患と非炎症性筋疾患の鑑別方法 |
| CN105316404B (zh) * | 2015-02-27 | 2017-02-22 | 中南大学湘雅二医院 | 系统性红斑狼疮生物标志物及其诊断试剂盒 |
| EP3426298A4 (en) | 2016-03-10 | 2019-11-27 | Viela Bio, Inc. | ILT7-BINDING MOLECULES AND METHOD OF USE THEREOF |
| CN105567861B (zh) * | 2016-03-16 | 2018-12-14 | 宫蕊 | Ifi27作为冠心病诊断标志物的用途 |
| SG11202108679PA (en) * | 2019-02-15 | 2021-09-29 | Astrazeneca Ab | Type i interferon-mediated disorders |
| JP2023501462A (ja) | 2019-11-11 | 2023-01-18 | アストラゼネカ・アクチエボラーグ | 全身性エリテマトーデスにおけるｉ型インターフェロン阻害 |
| IL298299A (en) | 2020-05-29 | 2023-01-01 | Astrazeneca Ab | Treatment of cardiometabolic disease with inhibitors of type i interferon signalling |
| AR123650A1 (es) * | 2020-10-02 | 2022-12-28 | Celgene Corp | Métodos para el tratamiento del lupus eritematoso sistémico y el uso de biomarcadores como un predictor de sensibilidad clínica a terapias |
| TW202237647A (zh) | 2020-10-08 | 2022-10-01 | 瑞典商阿斯特捷利康公司 | 狼瘡發作之治療 |
| CN116997359A (zh) | 2020-11-18 | 2023-11-03 | 阿斯利康(瑞典)有限公司 | 类固醇节制 |
| WO2022223770A1 (en) | 2021-04-23 | 2022-10-27 | Astrazeneca Ab | Treatment of cutaneous lupus erythematous |
| MX2023012465A (es) | 2021-04-23 | 2024-04-04 | Astrazeneca Ab | Regimen de dosificacion de anti-ifnar1 para inyeccion subcutanea. |
| PT4192882T (pt) | 2021-04-23 | 2025-05-02 | Astrazeneca Ab | Tratamento de nefrite lúpica com anticorpo anifrolumab de recetor inf anti-tipo i |
| US20240287176A1 (en) * | 2021-05-04 | 2024-08-29 | Viela Bio, Inc. | Methods of treatment of autoimmune disorders using ilt7 binding proteins |
| IL308128A (en) | 2021-05-12 | 2023-12-01 | Astrazeneca Ab | Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythematosus patients |
| WO2023006700A1 (en) | 2021-07-27 | 2023-02-02 | Astrazeneca Ab | Treatment of lupus |
| EP4412641A2 (en) | 2021-10-04 | 2024-08-14 | Astrazeneca AB | Treatment of lupus |
| CA3266513A1 (en) | 2022-09-14 | 2024-03-21 | Viatris Asia Pacific Pte. Ltd. | S1P1 RECEPTOR MODULATORS INTENDED FOR USE IN THE TREATMENT OF TYPE 1 IFN-MEDICATED DISEASES |
| CN120344259A (zh) | 2022-10-13 | 2025-07-18 | 阿斯利康(瑞典)有限公司 | 狼疮的治疗 |
| WO2024241156A1 (en) | 2023-05-19 | 2024-11-28 | Astrazeneca Ab | Treatment of lupus |
| WO2025022280A1 (en) | 2023-07-21 | 2025-01-30 | Astrazeneca Ab | Treatment of neurodegenerative diseases |
| GB202315831D0 (en) | 2023-10-16 | 2023-11-29 | Astrazeneca Ab | Treatment of skin disease |
| GB202402824D0 (en) | 2024-02-28 | 2024-04-10 | Astrazeneca Ab | Treatment of chronic kidney disease |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1984003106A1 (en) | 1983-02-04 | 1984-08-16 | Wadley Inst Of Molecular Medic | Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins |
| GB8303165D0 (en) | 1983-02-04 | 1983-03-09 | Secher D S | Monoclonal antibody |
| DE3306060A1 (de) | 1983-02-22 | 1984-08-23 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung |
| EP0205404B1 (en) | 1985-06-11 | 1992-07-15 | Ciba-Geigy Ag | Hybrid interferons |
| US7247425B2 (en) * | 1998-01-30 | 2007-07-24 | Evolutionary Genomics, Llc | Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions |
| US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| AU2004293369A1 (en) * | 2003-03-03 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the treatment of systemic lupus erythematosis |
| CA2458085A1 (en) * | 2003-03-21 | 2004-09-21 | F. Hoffmann-La Roche Ag | Transcriptional activity assay |
| EP1631590B1 (en) | 2003-04-23 | 2011-07-27 | Medarex, Inc. | Humanized antibodies to interferon alpha receptor-1 (ifnar-1) |
| KR101151477B1 (ko) | 2003-12-10 | 2012-06-22 | 메다렉스, 인코포레이티드 | 인터페론 알파 항체 및 그의 용도 |
| JP2007527247A (ja) * | 2004-03-05 | 2007-09-27 | ロゼッタ インファーマティクス エルエルシー | 臨床的基準および情報提供性遺伝子セットの組合せを使用する乳癌患者の分類 |
| JP5160887B2 (ja) | 2004-06-21 | 2013-03-13 | メダレックス インコーポレイテッド | インターフェロンアルファレセプター１抗体及びその使用法 |
| EP1945800B1 (en) * | 2005-08-05 | 2012-03-14 | Genentech, Inc. | Methods and compositions for detecting autoimmune disorders |
| WO2007123765A2 (en) * | 2006-03-31 | 2007-11-01 | Human Genome Sciences Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
| WO2008016356A2 (en) * | 2006-08-02 | 2008-02-07 | Genizon Biosciences | Genemap of the human genes associated with psoriasis |
| RU2527068C2 (ru) * | 2006-12-06 | 2014-08-27 | Медиммун, Ллк | Фармакодинамические маркеры, индуцированные интерфероном альфа |
| JP2010526107A (ja) * | 2007-05-03 | 2010-07-29 | メディミューン，エルエルシー | 自己免疫疾患の自己抗体マーカー |
| US20100209914A1 (en) * | 2007-05-25 | 2010-08-19 | Ore Pharmaceuticals , Inc. | Methods, systems, and kits for evaluating multiple sclerosis |
| MX2010008698A (es) * | 2008-02-08 | 2010-12-20 | Medimmune Llc | Marcadores de enfermedad y usos de los mismos. |
| KR20110014979A (ko) * | 2008-04-21 | 2011-02-14 | 노파르티스 포르슝스티프퉁 쯔바이크니덜라쑹 프리드리히 미셔 인스티튜트 포 바이오메디칼 리서치 | 항바이러스 요법 |
| US20090325176A1 (en) * | 2008-06-05 | 2009-12-31 | Wyeth | Gene Expression Profiles Associated with Asthma Exacerbation Attacks |
-
2010
- 2010-09-02 PT PT108145137T patent/PT2473636T/pt unknown
- 2010-09-02 BR BR112012004781A patent/BR112012004781A2/pt not_active IP Right Cessation
- 2010-09-02 ES ES10814513.7T patent/ES2613055T3/es active Active
- 2010-09-02 AU AU2010289383A patent/AU2010289383B2/en not_active Ceased
- 2010-09-02 CN CN2010800447566A patent/CN102753704A/zh active Pending
- 2010-09-02 LT LTEP10814513.7T patent/LT2473636T/lt unknown
- 2010-09-02 PL PL10814513T patent/PL2473636T3/pl unknown
- 2010-09-02 ME MEP-2017-24A patent/ME02599B/me unknown
- 2010-09-02 SI SI201031376A patent/SI2473636T1/sl unknown
- 2010-09-02 SM SM20170063T patent/SMT201700063T1/it unknown
- 2010-09-02 RU RU2012112802/10A patent/RU2012112802A/ru not_active Application Discontinuation
- 2010-09-02 HR HRP20170091TT patent/HRP20170091T1/hr unknown
- 2010-09-02 WO PCT/US2010/047721 patent/WO2011028933A1/en not_active Ceased
- 2010-09-02 US US13/393,616 patent/US20120251546A1/en not_active Abandoned
- 2010-09-02 CA CA2772921A patent/CA2772921A1/en not_active Abandoned
- 2010-09-02 JP JP2012528058A patent/JP5727484B2/ja not_active Expired - Fee Related
- 2010-09-02 KR KR1020127008547A patent/KR20120101340A/ko not_active Withdrawn
- 2010-09-02 EP EP10814513.7A patent/EP2473636B1/en active Active
- 2010-09-02 RS RS20170089A patent/RS55641B1/sr unknown
- 2010-09-02 DK DK10814513.7T patent/DK2473636T3/en active
- 2010-09-02 HU HUE10814513A patent/HUE032917T2/hu unknown
- 2010-09-02 MX MX2012002640A patent/MX2012002640A/es not_active Application Discontinuation
-
2015
- 2015-03-18 US US14/662,134 patent/US20150191788A1/en not_active Abandoned
- 2015-04-02 JP JP2015075518A patent/JP2015147788A/ja active Pending
- 2015-10-06 US US14/876,549 patent/US20160024205A1/en not_active Abandoned
-
2017
- 2017-01-26 CY CY20171100112T patent/CY1118566T1/el unknown
- 2017-01-26 SM SM201700063T patent/SMT201700063B/it unknown